ClinicalTrials.gg
RecruitingNCT07483567Updated Jun 2, 2026

IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 2 interventional study of IBI343,sintilimab,oxaliplatin,S-1 and sintilimab,oxaliplatin,S-1 in CLDN18.2 Positive, Primary Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a prospective, randomized, open, multicenter phase II clinical trial. It plans to enroll 70 participants with locally advanced gastric and gastroesophageal junction adenocarcinoma (G/GEJ AC) who are assessed as suitable for D2 radical surgery and capable of R0 resection.To evaluate the clinical efficacy and tolerability of IBI343 in combination with sintilimab and SOX regimen for perioperative treatment of resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.Enroll patients who are CLDN18.2 positive.

02

Conditions studied

  • CLDN18.2 Positive
  • Primary Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written and able to comply with the visit and related procedures as specified in the protocol.
  2. Male or female, 18 years ≤ age ≤ 75 years;
  3. score 0-1;
  4. confirmed, previously untreated patients with gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction; only Siewert II/III type participants are allowed for gastroesophageal junction cancer;
  5. Clinical staging based on enhanced CT/MRI examination, clinical stage T3\~4a with positive lymph nodes, and no distant ;
  6. The research center and surgeon can perform radical D2 lymph node dissection surgery, R0 resection;
  7. Physical condition and organ function allow for major abdominal surgery;
  8. Confirmed CLDN18.2 expression by central laboratory pathological tissue testing.
  9. Adequate organ and bone marrow function.
  10. Echocardiography confirms (LVEF) ≥ 50%;
  11. Female participants must agree not to breastfeed from screening through the entire treatment period and up to 6 months after the last dose.
  12. Female participants of or male participants whose partners are of childbearing potential must use effective from screening through the entire treatment period and up to 9 months after the last dose.

Exclusion criteria

Exclusion criteria

  1. positive.
  2. Currently participating in another interventional clinical study, except for those in the follow-up phase of an interventional study.
  3. Previous use of traditional Chinese medicine, Chinese patent medicines, or immunomodulators must be ≥2 weeks before starting the study medication.
  4. Received treatment with a strong inhibitor within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of the study drug.
  5. Received any within 4 weeks prior to the first dose of the study drug or plans to receive any during the study period.
  6. Underwent major surgery (craniotomy, thoracotomy, laparotomy, laparoscopic resection of significant tissues or organs, or other as defined by the investigator, excluding needle ) within 4 weeks prior to the first dose of the study drug, or has unhealed wounds, ulcers, or fractures.
  7. Patients who received (>10 mg/day prednisone equivalent) or other drugs within 14 days before enrollment. However, patients are allowed to enroll if they use topical or inhaled steroids, or adrenal replacement therapy with ≤10 mg/day prednisone equivalent, without active disease.
  8. History of interstitial lung disease, non-infectious pneumonia, severely impaired pulmonary function, or uncontrolled pulmonary disease such as pulmonary fibrosis, severe radiation pneumonitis, acute lung injury, etc., or suspected of having such conditions during the screening period.
  9. Presence of uncontrolled diseases, such as:

    • Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg).
  10. Any arterial thromboembolic event within 6 months prior to the first dose of the study drug, including myocardial infarction, unstable angina, cerebrovascular accident, , etc.
  11. History of deep vein thrombosis (patients stable on anticoagulation for at least 2 weeks can be enrolled), pulmonary embolism, or any other serious venous thromboembolic event within 3 months prior to the first dose of the study drug (implantable venous port or catheter-related thrombosis, or superficial venous thrombosis, are not considered "serious" venous thromboembolic events).
  12. Any life-threatening bleeding event or Grade 3 or 4 gastrointestinal/variceal bleeding event requiring transfusion, endoscopic, or surgical intervention within 3 months prior to the first dose of the study drug.
  13. Hepatic encephalopathy, hepatorenal syndrome, B or more severe liver cirrhosis.
  14. Complete or partial intestinal obstruction present during the screening period or history of complete or partial intestinal obstruction within 3 months prior to the first dose of the study drug, or risk of bowel perforation (including but not limited to acute diverticulitis, history of intra-abdominal abscess) or history of inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive small bowel resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.
  15. Other acute or chronic diseases or laboratory abnormalities that may result in: increased risk related to participation in the study or administration of the study drug, interference with the interpretation of study results, and participants deemed ineligible for the study by the investigator.
  16. Uncontrolled metabolic disorders or other non-malignant organ or systemic diseases or secondary reactions to cancer (such as leukemoid reaction, etc.), which may lead to higher medical risks and/or uncertainty in survival evaluation.
  17. Neurological, psychiatric, or social conditions that: affect compliance with study requirements, significantly increase the risk of adverse events, or impair the ability of the participant to provide written .
  18. History of other primary malignant tumors.
  19. Known history of immunodeficiency.
  20. History of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  21. History of allergic reactions to the drugs used in this study.
  22. Other conditions deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    experimental group

    Drug: IBI343,sintilimab,oxaliplatin,S-1

  • Active comparator
    control group

    Drug: sintilimab,oxaliplatin,S-1

Interventions

06

What researchers measure

Primary outcomes

  1. Pathological complete response rate (pCR rate): defined as the proportion of participants who, after surgery, show complete regression of tumor cells in the primary lesion and lymph node lesions according to pathological examination.

    Time frame: Up to 4 years

  2. Dose-limiting toxicity (DLT), to determine MTD and/or RP2D

    Time frame: Up to 4 years

Secondary outcomes

  1. Event-free survival (EFS)

    Defined as the time from the first dose (randomization) to the first determination of disease progression according to RECIST v1.1, or inability to undergo surgery or need for a change in treatment due to disease progression, local recurrence after surgery or distant metastasis, or death from any cause.

    Time frame: Up to 4 years

  2. Major pathologic response rate (MPR):The proportion of participants with postoperative pathology showing residual tumor cells ≤10%.

    Time frame: Up to 2 years

  3. Clinical downstaging rate (T and/or N downstaging):The proportion of participants who are ypT0, ypN0, and have a downstaging in preoperative imaging clinical staging compared to baseline imaging clinical staging.

    Time frame: Up to 2 years

  4. 3-year disease-free survival (3y-DFS):Defined as the time from R0 resection to the first recorded disease recurrence, metastasis, or death from any cause.

    Time frame: Up to 2 years

  5. 5-year overall survival (5y-OS):Defined as the time from the first dose or randomization date to death from any cause.

    Time frame: Up to 2 years

  6. Preoperative objective response rate (ORR) evaluated according to RECIST v1.1.

    Time frame: Up to 2 years

  7. Preoperative disease control rate (DCR) evaluated according to RECIST v1.1.

    Time frame: Up to 2 years

  8. Adverse Event (AE) incidence and correlation with the investigational drug

    Time frame: Up to 2 years

  9. Treatment-Emergent Adverse Event (TEAE) incidence and correlation with the investigational drug.

    Time frame: Up to 2 years

  10. Adverse Event of Special Interest (AESI) incidence and correlation with the investigational drug.

    Time frame: Up to 2 years

  11. Serious Adverse Event (SAE) incidence and correlation with the investigational drug.

    Time frame: Up to 2 years

  12. Incidence of perioperative complications and their correlation with the investigational drug.

    Time frame: Up to 2 years

  13. Area under the curve of drug concentration over time for participants treated with IBI343.

    Time frame: Up to 2 years

  14. Maximum concentration (Cmax) for participants treated with IBI343.

    Time frame: Up to 2 years

  15. Clearance (CL) for participants treated with IBI343.

    Time frame: Up to 2 years

  16. Volume of distribution (V) for participants treated with IBI343.

    Time frame: Up to 2 years

  17. Half-life for participants treated with IBI343.

    Time frame: Up to 2 years

  18. Positive rate of anti-drug antibodies for participants treated with IBI343.

    Time frame: Up to 2 years

  19. Positive rate of neutralizing antibodies for participants treated with IBI343.

    Time frame: Up to 2 years

  20. The number of participants with abnormal laboratory test results

    Time frame: Up to 2 years

  21. the number of participants showing clinically significant findings during physical examination

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jun 2030, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
Apr 17, 2026
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2031
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07483567
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Apr 17, 2026
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Jun 2, 2026

Study contacts

Shuang Han
Contact
shuang.han@innoventbio.com
+8651269566088

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Arcotatug tavatecan · Sintilimab · Oxaliplatin · Tegafur · Gimeracil · Oxonic Acid

Start the discussion